Treatment of EBV-associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab.
Pediatr Blood Cancer
; 62(11): 2018-20, 2015 Nov.
Article
em En
| MEDLINE
| ID: mdl-26109475
ABSTRACT
Patients with ataxia telangiectasia (AT) with malignancies face poor prognosis due to increased treatment-related toxicity. Here, we report a 14-year-old male with AT and Hodgkin lymphoma (HL) who received brentuximab vedotin and reduced COPP plus rituximab courses. This treatment resulted in complete remission and showed no severe toxicity.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Ataxia Telangiectasia
/
Doença de Hodgkin
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Herpesvirus Humano 4
/
Imunoconjugados
/
Infecções por Vírus Epstein-Barr
/
Rituximab
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article